2025-02-04 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
NUTX
Nutex Health Inc.
|
Buy |
15.15% |
53.16% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.49% |
-4% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.82% |
-0.57% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.4% |
2.4% |
2025-01-17 |
AGEN
Agenus Inc.
|
Buy |
8.53% |
-8.36% |
2025-01-22 |
BLFS
BioLife Solutions, Inc.
|
Buy |
9.56% |
-5.94% |
2025-01-30 |
RGNX
REGENXBIO Inc.
|
Buy |
8.1% |
-3.1% |
2025-02-03 |
The percentage of cash held in the portfolio is:
29.96%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
AXGN |
Sell
All
|
-1.81% |
INSM |
Sell
All
|
12.98% |
SIGA |
Sell
All
|
-9.55% |
Assets Rebalanced
None
2025-02-03 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
AXGN
AxoGen, Inc.
|
Buy |
9.65% |
-0.22% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
10.74% |
11.1% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
14.42% |
48.84% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.61% |
-0.8% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.66% |
-0.14% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.93% |
10.51% |
2025-01-17 |
AGEN
Agenus Inc.
|
Buy |
9.04% |
-0.78% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
7.16% |
-6.42% |
2025-01-23 |
BLFS
BioLife Solutions, Inc.
|
Buy |
9.61% |
-3.5% |
2025-01-30 |
RGNX
REGENXBIO Inc.
|
Buy |
8.18% |
0% |
2025-02-03 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
TGTX |
Sell
All
|
-0.69% |
Assets Rebalanced
None
2025-01-30 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
AXGN
AxoGen, Inc.
|
Buy |
9.7% |
0.33% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
10.94% |
13.16% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
13.55% |
39.94% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.14% |
-5.6% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.8% |
1.36% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
10.25% |
14.11% |
2025-01-17 |
AGEN
Agenus Inc.
|
Buy |
8.59% |
-5.74% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
7.49% |
-2.03% |
2025-01-23 |
TGTX
TG Therapeutics, Inc.
|
Buy |
8.61% |
4.54% |
2025-01-28 |
BLFS
BioLife Solutions, Inc.
|
Buy |
9.95% |
0% |
2025-01-30 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
AORT |
Sell
All
|
3.27% |
Assets Rebalanced
None
2025-01-28 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
AORT
Artivion, Inc.
|
Buy |
9.95% |
1.36% |
2025-01-09 |
AXGN
AxoGen, Inc.
|
Buy |
9.64% |
-1.75% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
11.05% |
12.62% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
12.43% |
26.44% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.63% |
-2% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
10.29% |
4.86% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
10.24% |
12.31% |
2025-01-17 |
AGEN
Agenus Inc.
|
Buy |
8.69% |
-6.01% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
7.71% |
-0.78% |
2025-01-23 |
TGTX
TG Therapeutics, Inc.
|
Buy |
8.36% |
0% |
2025-01-28 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
ESPR |
Sell
All
|
-14.96% |
Assets Rebalanced
None
2025-01-23 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
AORT
Artivion, Inc.
|
Buy |
9.94% |
1.82% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.18% |
-5.98% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
10.1% |
3.51% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
11.11% |
13.81% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
11.64% |
19.09% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
10.17% |
4% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.81% |
0.5% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.53% |
5.11% |
2025-01-17 |
AGEN
Agenus Inc.
|
Buy |
8.79% |
-4.44% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
7.73% |
0% |
2025-01-23 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
BLUE |
Sell
All
|
-20.97% |
Assets Rebalanced
None
2025-01-22 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
BLUE
bluebird bio, Inc.
|
Buy |
7.95% |
-17.94% |
2025-01-07 |
AORT
Artivion, Inc.
|
Buy |
10.13% |
4.5% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.91% |
-8.12% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
10.07% |
3.95% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
10.79% |
11.34% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
11.68% |
20.31% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
10.09% |
4% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.69% |
0% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.55% |
6.01% |
2025-01-17 |
AGEN
Agenus Inc.
|
Buy |
9.13% |
0% |
2025-01-22 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
TNDM |
Sell
All
|
-5.5% |
Assets Rebalanced
None
2025-01-17 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.84% |
0.47% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
8.15% |
-16.73% |
2025-01-07 |
AORT
Artivion, Inc.
|
Buy |
10.12% |
3.34% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.46% |
-3.42% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
9.89% |
0.99% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
10.34% |
5.54% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
11.61% |
18.31% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.85% |
0.4% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.64% |
-1.64% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.1% |
0% |
2025-01-17 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
MDRX |
Sell
All
|
-6.56% |
Assets Rebalanced
None
2025-01-16 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.65% |
-3.76% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
8.38% |
-16.43% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.58% |
-4.51% |
2025-01-08 |
AORT
Artivion, Inc.
|
Buy |
9.98% |
-0.56% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.48% |
-5.56% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
10.3% |
2.63% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
10.22% |
1.84% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
10.27% |
2.16% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
10.09% |
0.4% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
10.04% |
0% |
2025-01-16 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
ARDX |
Sell
All
|
0.19% |
Assets Rebalanced
None
2025-01-15 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.69% |
-4.19% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
8.17% |
-19.25% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.44% |
-6.67% |
2025-01-08 |
AORT
Artivion, Inc.
|
Buy |
9.94% |
-1.82% |
2025-01-09 |
ARDX
Ardelyx, Inc.
|
Buy |
10.65% |
5.24% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.69% |
-4.27% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
10.11% |
-0.05% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
10.03% |
-0.93% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
10.14% |
0% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
10.14% |
0% |
2025-01-15 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-14 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.65% |
-3.07% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
8.52% |
-14.42% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.7% |
-2.56% |
2025-01-08 |
AORT
Artivion, Inc.
|
Buy |
9.66% |
-2.94% |
2025-01-09 |
ARDX
Ardelyx, Inc.
|
Buy |
10.96% |
10.11% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.7% |
-2.56% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
9.95% |
0% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
9.95% |
0% |
2025-01-14 |
The percentage of cash held in the portfolio is:
21.91%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-13 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.7% |
-3.63% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
8.59% |
-14.72% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.82% |
-2.46% |
2025-01-08 |
AORT
Artivion, Inc.
|
Buy |
9.95% |
-1.16% |
2025-01-09 |
ARDX
Ardelyx, Inc.
|
Buy |
9.56% |
-5.06% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
10.08% |
0% |
2025-01-13 |
The percentage of cash held in the portfolio is:
42.3%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-09 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
10% |
0.36% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
8.5% |
-14.72% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.72% |
-2.46% |
2025-01-08 |
AORT
Artivion, Inc.
|
Buy |
9.97% |
0% |
2025-01-09 |
ARDX
Ardelyx, Inc.
|
Buy |
9.97% |
0% |
2025-01-09 |
The percentage of cash held in the portfolio is:
51.84%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-08 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.82% |
-0.82% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
9% |
-9.07% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.9% |
0% |
2025-01-08 |
The percentage of cash held in the portfolio is:
71.29%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-07 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.8% |
0% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
9.8% |
0% |
2025-01-07 |
The percentage of cash held in the portfolio is:
80.4%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-12-26 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
PCRX |
Sell
All
|
NA |
Assets Rebalanced
None
2024-12-18 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PCRX
Pacira BioSciences, Inc.
|
Buy |
10.44% |
3.88% |
2024-12-05 |
The percentage of cash held in the portfolio is:
89.56%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
APLS |
Sell
All
|
5.82% |
MGNX |
Sell
All
|
-1.76% |
Assets Rebalanced
None
2024-12-12 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.71% |
4.2% |
2024-11-27 |
MGNX
MacroGenics, Inc.
|
Buy |
10.31% |
0.29% |
2024-11-27 |
PCRX
Pacira BioSciences, Inc.
|
Buy |
10.67% |
6.5% |
2024-12-05 |
The percentage of cash held in the portfolio is:
68.32%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
ESPR |
Sell
All
|
-13.23% |
Assets Rebalanced
None
2024-12-10 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.64% |
7.32% |
2024-11-27 |
MGNX
MacroGenics, Inc.
|
Buy |
10.15% |
2.35% |
2024-11-27 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
12.13% |
23.55% |
2024-12-03 |
PCRX
Pacira BioSciences, Inc.
|
Buy |
9.67% |
0% |
2024-12-05 |
The percentage of cash held in the portfolio is:
57.41%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
RVNC |
Sell
All
|
-27.34% |
Assets Rebalanced
None
2024-12-05 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.18% |
4.6% |
2024-11-27 |
MGNX
MacroGenics, Inc.
|
Buy |
9.99% |
2.65% |
2024-11-27 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
11.38% |
18.06% |
2024-12-03 |
RVNC
Revance Therapeutics, Inc.
|
Buy |
9.49% |
0% |
2024-12-05 |
PCRX
Pacira BioSciences, Inc.
|
Buy |
9.49% |
0% |
2024-12-05 |
The percentage of cash held in the portfolio is:
49.46%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
ARWR |
Sell
All
|
-11.63% |
Assets Rebalanced
None
2024-12-03 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.52% |
8.55% |
2024-11-27 |
MGNX
MacroGenics, Inc.
|
Buy |
10.52% |
8.53% |
2024-11-27 |
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.76% |
0.73% |
2024-11-28 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.6% |
0% |
2024-12-03 |
The percentage of cash held in the portfolio is:
59.6%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
FATE |
Sell
All
|
-6.62% |
Assets Rebalanced
None
2024-11-28 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.14% |
4.63% |
2024-11-27 |
MGNX
MacroGenics, Inc.
|
Buy |
10.37% |
7.06% |
2024-11-27 |
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.69% |
0% |
2024-11-28 |
FATE
Fate Therapeutics, Inc.
|
Buy |
9.69% |
0% |
2024-11-28 |
The percentage of cash held in the portfolio is:
60.12%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-11-27 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.8% |
0% |
2024-11-27 |
MGNX
MacroGenics, Inc.
|
Buy |
9.8% |
0% |
2024-11-27 |
The percentage of cash held in the portfolio is:
80.4%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-11-26 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
CORT |
Sell
All
|
17.92% |
Assets Rebalanced
None
2024-11-21 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
CORT
Corcept Therapeutics Incorporated
|
Buy |
10.51% |
12.05% |
2024-11-05 |
The percentage of cash held in the portfolio is:
89.49%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
IRTC |
Sell
All
|
-9.45% |
Assets Rebalanced
None
2024-11-20 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
IRTC
iRhythm Technologies, Inc.
|
Buy |
8.7% |
-7.33% |
2024-11-05 |
CORT
Corcept Therapeutics Incorporated
|
Buy |
10.19% |
8.49% |
2024-11-05 |
The percentage of cash held in the portfolio is:
81.11%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
NEOG |
Sell
All
|
5.23% |
MGNX |
Sell
All
|
-10.08% |
Assets Rebalanced
None
2024-11-19 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
NEOG
Neogen Corporation
|
Buy |
8.24% |
6% |
2024-10-30 |
MGNX
MacroGenics, Inc.
|
Buy |
8.22% |
-9.3% |
2024-11-04 |
IRTC
iRhythm Technologies, Inc.
|
Buy |
8.86% |
-5.62% |
2024-11-05 |
CORT
Corcept Therapeutics Incorporated
|
Buy |
9.87% |
5.11% |
2024-11-05 |
The percentage of cash held in the portfolio is:
64.81%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
HCSG |
Sell
All
|
2.56% |
Assets Rebalanced
None
2024-11-18 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
HCSG
Healthcare Services Group, Inc.
|
Buy |
14.17% |
5.39% |
2024-10-29 |
NEOG
Neogen Corporation
|
Buy |
7.88% |
1.81% |
2024-10-30 |
MGNX
MacroGenics, Inc.
|
Buy |
8.32% |
-7.75% |
2024-11-04 |
IRTC
iRhythm Technologies, Inc.
|
Buy |
9.23% |
-1.22% |
2024-11-05 |
CORT
Corcept Therapeutics Incorporated
|
Buy |
9.68% |
3.54% |
2024-11-05 |
The percentage of cash held in the portfolio is:
50.72%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
RGEN |
Sell
All
|
-17.11% |
Assets Rebalanced
None
2024-11-15 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
HCSG
Healthcare Services Group, Inc.
|
Buy |
14.2% |
8.95% |
2024-10-29 |
NEOG
Neogen Corporation
|
Buy |
7.65% |
2.09% |
2024-10-30 |
MGNX
MacroGenics, Inc.
|
Buy |
8.61% |
-1.55% |
2024-11-04 |
IRTC
iRhythm Technologies, Inc.
|
Buy |
9.28% |
2.46% |
2024-11-05 |
CORT
Corcept Therapeutics Incorporated
|
Buy |
9.92% |
9.45% |
2024-11-05 |
RGEN
Repligen Corporation
|
Buy |
9.53% |
-5.34% |
2024-11-14 |
The percentage of cash held in the portfolio is:
40.81%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
SAGE |
Sell
All
|
-15.03% |
ALT |
Sell
All
|
-10.91% |
Assets Rebalanced
None
2024-11-14 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
HCSG
Healthcare Services Group, Inc.
|
Buy |
13.99% |
11.32% |
2024-10-29 |
NEOG
Neogen Corporation
|
Buy |
7.66% |
5.86% |
2024-10-30 |
MGNX
MacroGenics, Inc.
|
Buy |
8.22% |
-2.58% |
2024-11-04 |
IRTC
iRhythm Technologies, Inc.
|
Buy |
9.35% |
6.99% |
2024-11-05 |
CORT
Corcept Therapeutics Incorporated
|
Buy |
9.86% |
12.76% |
2024-11-05 |
SAGE
Sage Therapeutics, Inc.
|
Buy |
7.67% |
-9.34% |
2024-11-08 |
ALT
Altimmune, Inc.
|
Buy |
12.12% |
0.32% |
2024-11-13 |
RGEN
Repligen Corporation
|
Buy |
9.71% |
0% |
2024-11-14 |
The percentage of cash held in the portfolio is:
21.42%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
CARA |
Sell
All
|
-6.09% |
CDMO |
Sell
All
|
17.76% |
Assets Rebalanced
None
2024-11-13 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
CDMO
Avid Bioservices, Inc.
|
Buy |
8.94% |
18.05% |
2024-10-24 |
HCSG
Healthcare Services Group, Inc.
|
Buy |
14.04% |
13.61% |
2024-10-29 |
NEOG
Neogen Corporation
|
Buy |
7.61% |
6.97% |
2024-10-30 |
MGNX
MacroGenics, Inc.
|
Buy |
8.79% |
5.94% |
2024-11-04 |
IRTC
iRhythm Technologies, Inc.
|
Buy |
9.2% |
7.07% |
2024-11-05 |
CORT
Corcept Therapeutics Incorporated
|
Buy |
9.92% |
15.44% |
2024-11-05 |
CARA
Cara Therapeutics, Inc.
|
Buy |
8.22% |
-1.16% |
2024-11-08 |
SAGE
Sage Therapeutics, Inc.
|
Buy |
7.54% |
-9.34% |
2024-11-08 |
ALT
Altimmune, Inc.
|
Buy |
11.87% |
0% |
2024-11-13 |
The percentage of cash held in the portfolio is:
13.87%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
IOVA |
Sell
All
|
-12.15% |
NUTX |
Sell
All
|
51.33% |
Assets Rebalanced
None
2024-11-08 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
NUTX
Nutex Health Inc.
|
Buy |
9.85% |
16.4% |
2024-10-23 |
CDMO
Avid Bioservices, Inc.
|
Buy |
8.9% |
18.15% |
2024-10-24 |
HCSG
Healthcare Services Group, Inc.
|
Buy |
13.18% |
7.31% |
2024-10-29 |
IOVA
Iovance Biotherapeutics, Inc.
|
Buy |
13.68% |
11.33% |
2024-10-29 |
NEOG
Neogen Corporation
|
Buy |
7.78% |
10.04% |
2024-10-30 |
MGNX
MacroGenics, Inc.
|
Buy |
9.5% |
15.25% |
2024-11-04 |
IRTC
iRhythm Technologies, Inc.
|
Buy |
9.31% |
8.99% |
2024-11-05 |
CORT
Corcept Therapeutics Incorporated
|
Buy |
9.27% |
8.47% |
2024-11-05 |
CARA
Cara Therapeutics, Inc.
|
Buy |
8.27% |
0% |
2024-11-08 |
SAGE
Sage Therapeutics, Inc.
|
Buy |
8.27% |
0% |
2024-11-08 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
NVRO |
Sell
All
|
-1.11% |
VREX |
Sell
All
|
17.93% |
Assets Rebalanced
None